Activin type I receptor polymorphisms and body composition in older individuals with sarcopenia-Analyses from the LACE randomised controlled trial.
Bashir T, Achison M, Adamson S, Akpan A, Aspray T, Avenell A, Band MM, Burton LA, Cvoro V, Donnan PT, Duncan GW, George J, Gordon AL, Gregson CL, Hapca A, Hume C, Jackson TA, Kerr S, Kilgour A, Masud T, McKenzie A, McKenzie E, Patel H, Pilvinyte K, Roberts HC, Rossios C, Sayer AA, Smith KT, Soiza RL, Steves CJ, Struthers AD, Tiwari D, Whitney J, Witham MD, Kemp PR.
Bashir T, et al. Among authors: kilgour a.
PLoS One. 2023 Nov 14;18(11):e0294330. doi: 10.1371/journal.pone.0294330. eCollection 2023.
PLoS One. 2023.
PMID: 37963137
Free PMC article.
Clinical Trial.
Body composition and muscle strength are at least in part genetically determined, consequently polymorphisms in pathways important in muscle biology (e.g., the activin/myostatin signalling pathway) are hypothesised to contribute to the development of sarcopenia. ...
Body composition and muscle strength are at least in part genetically determined, consequently polymorphisms in pathways important in muscle …